GOSSELIES, Belgium–(BUSINESS WIRE)–Regulatory News:
BONE THERAPEUTICS, the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces that it has established its US based subsidiary, Bone Therapeutics USA Inc. in Boston, Massachusetts, in line with its strategy as outlined at the time of its recent initial public offering. The establishment of the US headquarters is the first step for the Company to move forward its US clinical trials programme.
This new subsidiary of Bone Therapeutics is situated in Kendall Square, Cambridge. The world’s ten largest biopharma companies have a presence in Massachusetts, making it an ideal location for scientific and technological innovation and ideally suited for Bone Therapeutics’ first US foothold.
The creation of this affiliate is the first milestone in a process that will lead to the initiation of Bone Therapeutics’ clinical trials for fracture repair and osteonecrosis in the US.
Enrico Bastianelli, CEO of Bone Therapeutics, commented: “The creation of a subsidiary in the US is an important step forward in our strategy as set out at the time of the IPO. This further strengthens the international reach of our innovative pipeline of bone cell therapy products. We are very excited to become part of the biotechnology cluster in Cambridge and believe this prime location will prove to be extremely beneficial to the Company as we move our clinical development forward in this important market.”
